Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.24.1.u1
Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share                
Net earnings, including noncontrolling interest $ 49,059 $ 27,465 $ 50,993 $ 70,218 $ 50,005 $ 89,734 $ 127,517 $ 209,958
Less net earnings (loss) attributable to noncontrolling interest 0     0     0 179
Net earnings attributable to Bio-Techne 49,059     70,218     127,517 209,779
Income allocated to participating securities (5)     (16)     (24) (52)
Income available to common shareholders $ 49,054     $ 70,202     $ 127,493 $ 209,727
Weighted-average shares outstanding - basic (in shares) 157,309     157,311     157,655 157,071
Earnings per share - basic (in shares) $ 0.31     $ 0.45     $ 0.81 $ 1.34
Income available to common shareholders $ 49,054     $ 70,202     $ 127,493 $ 209,727
Dilutive effect of stock options and restricted stock units (in shares) 3,187     4,304     3,162 4,697
Weighted-average common shares outstanding - diluted (in shares) 160,496     161,615     160,817 161,768
Earnings per share - diluted (in shares) $ 0.31     $ 0.43     $ 0.79 $ 1.30